AbClon Inc. (KOSDAQ: 174900)

Market Cap	239.77B
Revenue (ttm)	2.40B
Net Income (ttm)	-18.18B
Shares Out	17.43M
EPS (ttm)	-1,112.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,271
Open	14,260
Previous Close	14,030
Day's Range	13,640 - 14,260
52-Week Range	10,830 - 22,150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2023, AbClon's revenue was 3.08 billion, a decrease of -9.50% compared to the previous year's 3.41 billion. Losses were -12.92 billion, 39.6% more than in 2022.